Morris, RW;
Cooper, JA;
Shah, T;
Wong, A;
Drenos, F;
Engmann, J;
McLachlan, S;
... UCLEB Consortium, .; + view all
(2016)
Marginal role for 53 common genetic variants in cardiovascular disease prediction.
Heart
10.1136/heartjnl-2016-309298.
(In press).
Preview |
Text (Published article)
Morris et al Marginal role for 53 common genetic variants in cardiovascular disease prediction Advance VoR.pdf Download (563kB) | Preview |
Preview |
Text (Supplementary information)
Morris et al Marginal role for 53 common genetic variants in cardiovascular disease prediction Supplementary.pdf Download (157kB) | Preview |
Abstract
OBJECTIVE: We investigated discrimination and calibration of cardiovascular disease (CVD) risk scores when genotypic was added to phenotypic information. The potential of genetic information for those at intermediate risk by a phenotype-based risk score was assessed. METHODS: Data were from seven prospective studies including 11 851 individuals initially free of CVD or diabetes, with 1444 incident CVD events over 10 years' follow-up. We calculated a score from 53 CVD-related single nucleotide polymorphisms and an established CVD risk equation 'QRISK-2' comprising phenotypic measures. The area under the receiver operating characteristic curve (AUROC), detection rate for given false-positive rate (FPR) and net reclassification improvement (NRI) index were estimated for gene scores alone and in addition to the QRISK-2 CVD risk score. We also evaluated use of genetic information only for those at intermediate risk according to QRISK-2. RESULTS: The AUROC was 0.635 for QRISK-2 alone and 0.623 with addition of the gene score. The detection rate for 5% FPR improved from 11.9% to 12.0% when the gene score was added. For a 10-year CVD risk cut-off point of 10%, the NRI was 0.25% when the gene score was added to QRISK-2. Applying the genetic risk score only to those with QRISK-2 risk of 10%-<20% and prescribing statins where risk exceeded 20% suggested that genetic information could prevent one additional event for every 462 people screened. CONCLUSION: The gene score produced minimal incremental population-wide utility over phenotypic risk prediction of CVD. Tailored prediction using genetic information for those at intermediate risk may have clinical utility.
Archive Staff Only
 |
View Item |
